Prostate Health | Medical XPRT
Articles & Whitepapers
-
What are the Possibilities for ADCs Targeting Trop2?
Antibody drug conjugate (ADC) research involves more and more targets, such as HER-2, Trop-2, Claudin-18.2, B7-H3 and B7-H4, etc. Trop-2 is a transmembrane glycoprotein. Its high expression is associated with the occurrence of many tumors and poor prognosis. It is a very popular ADC research target, second only to HER2. Currently, only Gilead's Trop-2 ADC drug Trodelvy has been approved for ...
-
FDA Approved Peptide Drugs in the First Half of 2023
The FDA's Center for Drug Evaluation and Research (CDER) regulatory approval of a total of 26 NME (New Molecular Entity) drugs in the first half of 2023. It is worth noting that the 26 drugs approved ...
News
-
Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Introduction Anliprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist ...
Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research
NICE Irreversible Electroporation for Treating Prostate Cancer Announcement
The Dutch Government Elects to Sponsor the ENFORCE Trial - A Fully Funded RCT That Includes the Nanoknife System for Prostate Treatment
Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting
Equipment & Solutions
-
Showcase
Injection
Used to treat hypercalcemia caused by malignant tumor or bone metastasis of multiple myeloma and solid cancer or prostate cancer.